详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia

文献详情

资源类型：

作者：

机构： [1]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN, [2]Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/CN, [3]Department of Thoracic Oncology, Jilin Province Cancer Hospital, Changchun/CN, [4]Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing/CN, [5]Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN, [6]Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN, [7]Bristol-Myers Squibb, Princeton, NJ/US, [8]Guangdong General Hospital, Guangzhou/CN

出处：

ISSN：

关键词： Nivolumab non-small cell lung cancer

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

第一作者：

第一作者机构： [1]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Efficacy and Safety of Nivolumab Therapy for Advanced NSCLC in the Expanded Access Named Patient Program in Taiwan [2]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [3]Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. [4]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [5]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [6]Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)(Open Access) [7]Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer [8]Overexpression of HN1L promotes cell malignant proliferation in non-small cell lung cancer [9]Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression [10]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells